The Phase II trial of Lutetium[177Lu] Oxodotreotide Injection, sponsored by Peking University, aims to establish the efficacy and safety of this treatment in patients with unresectable or metastatic GEP-NETs. Given the increasing prevalence of neuroendocrine tumors and the limited treatment options available, successful outcomes could position this therapy as a first-line treatment, potentially capturing significant market share in the oncology sector. The competitive landscape includes existing therapies such as somatostatin analogs and other peptide receptor radionuclide therapies (PRRTs). The trial's results may influence future treatment guidelines and reimbursement decisions, making it a critical asset for stakeholders in the oncology market.